

#19-2

DEPARTMENT OF THE AIR FORCE

HEADQUARTERS AIR FORCE OFFICE OF SPECIAL INVESTIGATIONS  
WASHINGTON, DC 20314



7 SEP 1979

REPLY TO  
ATTN OF:

IVG

SUBJECT:

HQ AFOSI Collection Requirement 50 (HQ CR 50)

TO:

All AFOSI USAFE Dists, Dets, and RAs (CAT VII)

1. Purpose. The purpose of this letter is to introduce HQ CR 50 which targets drug availability and drug trafficking in the USAFE Theater.
2. Concept and Application. This CR reduces a concept to practical application and, as such, is a test of the concept. The concept addresses two needs. One need is to develop an effective vehicle for reporting local drug availability information to local USAF users, including commanders and DAACCs. The other need is to develop a method for systematically collecting information concerning drug trafficking techniques which indicate direct USAF involvement; therefore, merit direct AFOSI interest and action. The CR describes the use of two new AFOSI Forms, 161 and 165, which are the formats you will use to collect and report responsive information from the local level.
3. AFOSI Form 161. Crime Information Report 79-1, "Computing and Reporting Drug Seizures" and the USAFE "Counterpush" experience focused the need for AFOSI Form 161, "AFOSI Illicit Drug Market Assessment." AFOSI units need the information to conduct offensive investigative activities and to prepare meaningful Reports of Investigation. Command needs the data to better assess their local problem. Additionally, the data is collected in a format which will permit multiple levels of analysis and is suitable for eventual computerization. Unfortunately, this form contains two typographical errors which should be corrected locally prior to dissemination. On the front side under "Drug Type" the word "heroin" is misspelled (HEORIN). On the back side under "Average Dosage Unit" the quantity for LSD should read "ug" (micrograms) instead of "mg" (milligrams).
4. AFOSI Form 165. Case Type 456 and 17/0, as well as substantive case files, focused the need for AFOSI Form 165, "AFOSI Report of Illicit Drug Trafficking." Crime Special Study 79-9, "Air Force Drug Trafficking in USAFE" pointed to the need for more sophisticated reporting formats in the important area of drug trafficking. The format which was developed is designed to generate significant and detailed data elements and to organize them in a way that permits relatively simple collation. The purpose of this process is to facilitate the exchange of information between districts and to

USAF review(s) completed.

produce reports, at HQ AFOSI, which will be sent back to the field in a form that is more useful than the original input. Inasmuch as this feedback will present the "big picture" it will enhance target selection and evidence gathering, thereby substantially improving our interdiction efforts.


5. Test Application. The USAFE Theater was chosen to test the application of this collections concept. "Counterpush" and the continuing high level interest in that action plan, is a major reason for the selection. The commendable AFOSI USAFE response to that plan suggests a test environment that will provide a thorough evaluation of this application of a concept.

6. Evaluation. While IVG will be evaluating the responses to the CR at the HQ AFOSI level, the bulk of the burden must rest with the agents, at all levels, who work with the CR. Your comments, critiques, and suggestions will aid immeasurably in helping us to refine the application of this concept and achieve a workable methodology that can be used worldwide.

7. Forms Distribution. HQ AFOSI/DAP is making initial distribution of these forms. Districts should initiate action to establish routine requirements for them. Emergency supplies are available from HQ AFOSI/DAP.

8. HQ CR 47. HQ CR 50 suspends the operation of HQ CR 47 in USAFE for the period of the HQ CR 50 suspense.

FOR THE COMMANDER



**HUGH W. BARBER, Jr., Lt Col, USAF**  
Asst Director of Criminal Investigations

1 Atch  
HQ CR 50

Cy to: AFOSI OL-G  
HQ AFOSI/IVC

DEPARTMENT OF THE AIR FORCE

HEADQUARTERS AIR FORCE OFFICE OF SPECIAL INVESTIGATIONS  
WASHINGTON, DC 20314



REPLY TO  
ATTN OF:

IVG

7 SEP 1979

SUBJECT:

Headquarters Collection Requirement 50 (HQ CR 50)

TO:

All AFOSI USAFE Dists, Dets, and RAs (CAT VII)

1. TARGET. Drug Availability and Illicit Drug Trafficking in the USAFE Theater.

2. BACKGROUND. CINCUSAFE has tasked AFOSI with significant responsibility for the interdiction of drug trafficking in the USAFE theater. Recent AFOSI investigations have again demonstrated that illicit trafficking is an important aspect of the overall drug problem. This CR establishes a systematic method for collecting, reporting and collating drug trafficking information pertinent to the USAF. If conscientiously applied, it should be an effective tool not only in assessing the extent of drug trafficking within USAFE, but also in planning operations to thwart drug trafficking by USAF and USAF-affiliated personnel. In some respects, the approach of this CR is innovative, but its message is tested and proven — the battle against drug abuse must be fought above the user level. This CR targets trafficking by use of USAF aircraft, and by USAF and USAF-affiliated personnel because that is where AFOSI's mission responsibilities and investigative jurisdiction most appropriately extend and where AFOSI has the greatest opportunity to interdict the drug trade.

3. INTERROGATORIES:

a. Identify drugs being abused by USAF and USAF-affiliated personnel. For each drug of abuse, provide:

(1) The weight/unit count, price and purity (where appropriate) of the usual illicit retail (street) level sale.

(2) The weight/unit count, price and purity (where appropriate) of the usual wholesale (dealer) level sale.

(3) An assessment concerning the local availability of the drug.

(4) When appropriate, amplifying remarks to explain unique factors associated with the drug, i.e., statements regarding the legality of over-the-counter dispensation in the local area; packaging data; street or slang name; etc.

b. Report trafficking patterns relating to the planned, alleged or actual use of USAF or USAF-contract aircraft in the illicit transport of drugs. In each instance, provide:

- (1) Date of incident.
- (2) Type, quantity and value of drugs.
- (3) Type of aircraft and its routing, to include point of origin, interim stops, and destination. Indicate specific locations where drugs were introduced onto and retrieved from the aircraft.
- (4) Smuggling method (i.e., secreted in drogue chute, stored in electrical panel, etc.); concealment technique (i.e., packaged in electrical tape, sealed in tinfoil, etc.); and arrangement for retrieval/delivery of drugs.
- (5) Subject identifying data, to include Air Force Specialty Code (AFSC), grade, duty status during incident (i.e., permanent party (Perm Party), TDY, LV, AFRes, ANG, etc.), permanent duty assignment location, and motive (i.e., profit, favor, unwitting, etc.) NOTE: Complete as much of the subject identifying data as possible if incident involves personnel of another US military department, military dependents or civilians authorized to travel on USAF aircraft.
- (6) An evaluation of source and information.
- (7) A reference to an AFOSI file number or source identification.

c. Report drug trafficking techniques planned, attempted or used by USAF or USAF-affiliated personnel when the incidents involve other than trafficking on USAF aircraft. In each instance, provide:

- (1) Date of incident.
- (2) Type, quantity and value of drugs.
- (3) Conveyance used; for example, mail; household goods (HHG) shipment; private, commercial or government auto (PA, CA, GA); private, commercial or government rail (PR, CR or GR); private, commercial or government bus (PB, CB or GB); private commercial or government vessel (PV, CV, or GV); or private or commercial plane (PP or CP).
- (4) Routing of the drug trafficker, smuggler or courier, or the drugs. Include point of origin, interim stops, destination, and location(s) where drugs were stored, delivered or received.

(5) Smuggling method (i.e., secreted in false bottom suitcase, taped to body, etc.); concealment technique (i.e., wrapped in rubber sealant, hidden in toothpaste tube, dissolved as a liquid etc.); and arrangements for retrieval or delivery.

(6) Subject identifying data (see para 3b(5), above).

(7) An evaluation of source and information.

(8) A reference to an AFOSI file number or source identification.

4. SPECIAL INSTRUCTIONS.

a. Reporting Standards.

(1) Report weights and values of drugs in metric terms and U.S. dollars, respectively.

(2) Do not include reports of seizures or arrests where the subject is merely in possession of personal use quantities of drugs unless a particular seizure is of local significance (e.g., new drug on the scene).

(3) Do not report unverified items from the press.

(4) Do not prepare a 456 when the information is non-specific and obviously unverifiable. For example, unsubstantiated information to the effect that USAF personnel are trafficking drugs between Turkey and Germany has no value unless some detail can be reported concerning the type of drug, method of trafficking or concealment, leads relating to the persons involved, etc. Do follow-up, however, by local targeting for additional details, e.g., identities of others who may have pertinent knowledge, enhanced "customs" inspections, etc.

(5) Do not use responses to this CR to circumvent or substitute for established AFOSI operational reporting requirements.

b. Reporting Formats. The following procedures apply:

(1) Information responsive to interrogatory 3a will be reported using the format reflected in Attachment 1, "AFOSI Illicit Drug Market Assessment," AFOSI Form 161. See HQ AFOSI/IVG Crime Information Report 79-1 for detailed guidance concerning the computing and reporting of drug data.

(2) Information responsive to interrogatory 3b will be reported using the format reflected in Attachment 2, "AFOSI Report of Illicit Drug Trafficking," AFOSI Form 165. Conduct thorough debriefings to ensure that the report has sufficient data to make it a meaningful measure of trafficking.

(3) Information responsive to interrogatory 3c also will be reported using the format reflected in Attachment 2.

c. Report Timing:

(1) AFOSI Illicit Drug Market Assessments will be reviewed by the preparing AFOSI unit at least monthly. Whenever there is an appreciable change in the type of drugs being abused, local availability, or weight, value or purity of drugs being encountered, an updated report will be prepared. Revalidated copies of the assessment will be sent to all distributees on a quarterly basis. A case type 456 number may be assigned to transmittal documents.


(2) Reports on Illicit Drug Trafficking will be submitted as soon as sufficient data is collected to provide meaningful information concerning planned (known or alleged) or actual incidents. A case type 456 number may be assigned to these reports.

5. SPECIALIZED DRUG ABUSE COLLECTIONS. Occasionally, AFOSI field units receive requests for recurring support of the collection requirements of other US agencies. For example, the Ambassador's drug abuse advisor or the local Drug Enforcement Administration (DEA) representative may request AFOSI to provide copies of periodic drug threats estimates prepared by host government agencies with whom AFOSI is the primary US point of liaison. When this type of tasking occurs, advise HQ AFOSI/IVGS of the request. Upon approval, reports responsive to these requests may be made using the case type 456 numbering system. Districts may immediately honor one time requests for support of this type and assign a 456 number, but should advise IVG of the reason for the report when they transmit the material to HQ AFOSI.

6. SUSPENSE: This CR will remain in effect for a period of one year.

7. DISTRIBUTION: As prescribed in AFOSIR 124-24, ensure that copies are sent to other AFOSI districts which have an interest in the reported information. AFOSI Illicit Drug Market Assessments also should be provided to USAF Drug and Alcohol Abuse Control Committees.

FOR THE COMMANDER



**HUGH W. BARBER, Jr., Lt Col, USAF**  
**Asst Director of Criminal Investigations**

- 2 Atch  
1. AFOSI Illicit Drug Market Assessment  
2. AFOSI Report of Illicit Drug Trafficking